3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Unknown
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Genitourinary
1
Breast
1
Conditions
Breast Neoplasms
20
Neoplasm Metastasis
4
Neoplasms
3
Melanoma
3
Thyroid Neoplasms
1
Thymus Neoplasms
1
Thrombosis
1
Thromboembolism
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma
1
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Ovarian Neoplasms
1
Osteosarcoma
1
Neoadjuvant Treatment for HER2-positive, ER-positive Breast Cancer
1
Lung Neoplasms
1
Leukemia, Myeloid, Acute
1
Inflammation
1
Immune System Diseases
1
Hormone Receptor Positive Advanced Breast Cancer
1
Head and Neck Neoplasms
1
HER2+ Breast Cancer
1
Gastrointestinal Neoplasms
1
Estrogen Receptor-positive Breast Cancer
1
Esophageal Squamous Cell Carcinoma
1
Endometrial Neoplasms
1
ER Positive, HER2 Negative Breast Cancer
1
Colonic Neoplasms
1
Chordoma
1
Cardiovascular Diseases
1
Interventions
Thyroidectomy
4
Iodine-131
4
trametinib
3
dabrafenib
3
apatinib
3
anlotinib
2
Surgical Procedures, Operative
2
Blood Specimen Collection
2
Biopsy, Large-Core Needle
2
toripalimab
1
tislelizumab
1
surufatinib
1
regorafenib
1
penpulimab
1
pembrolizumab
1
pazopanib
1
palbociclib
1
olaparib
1
lenvatinib
1
famitinib
1
camrelizumab
1
Ultrasonography
1
Thyroxine
1
Thyrotropin Alfa
1
Sunitinib
1
Second Harmonic Generation Microscopy
1
Routinely Collected Health Data
1
Rosiglitazone
1
Robotic Surgical Procedures
1
Radiotherapy, Intensity-Modulated
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Thyroid Neoplasms
×
palbociclib
×
Clear all
NCT05949424
2023-11-29
OPTI-DOSE
University Medical Center Groningen
Phase 4
Unknown
30 enrolled